Table 3. Multivariate analyses of disease outcome according to BMI.

	All		Tamoxifen		Tamoxifen+aminogluthtetimide
DFS	HR	95% CI	HR	95% CI	HR	95% CI
Overweight+obese vs normal weight	1.25	0.95–1.64	1.27	0.86–1.87	1.23	0.83–1.82
Overweight vs normal weight	1.15	0.85–1.55	1.35	0.89–2.04	0.99	0.64–1.53
Obese vs normal weight	1.45	1.03–2.02	1.15	0.70–1.87	1.78	1.12–2.83
Distant recurrence-free survival
Overweight+obese vs normal weight	1.62	1.09–2.42	1.48	0.85–2.58	1.81	1.02–3.22
Overweight vs normal weight	1.54	1.00–2.35	1.58	0.88–2.86	1.51	0.81–2.83
Obese vs normal weight	1.79	1.11–2.87	1.31	0.66–2.60	2.43	1.25–4.70
Overall survival
Overweight+obese vs normal weight	1.49	0.99–2.23	1.29	0.74–2.24	1.73	0.96–3.13
Overweight vs normal weight	1.34	0.87–2.07	1.22	0.66–2.24	1.48	0.78–2.80
Obese vs normal weight	1.81	1.12–2.91	1.41	0.71–2.77	2.28	1.16–4.51

Abbreviation: BMI=body mass index; CI=confidence interval; DFS=disease-free survival; HR=hazard ratio.